ECRG2 regulates ECM degradation and uPAR/FPRL1 pathway contributing cell invasion/migration

Cancer Letters

Volumn 290, Issue 1, 2010, Pages 87-95

  Cheng, Xiaolong ^a   Lu, Shih Hsin ^b   Cui, Yongping ^a,c  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

ECRG2; FPRL1; Invasion migration; uPA uPAR

Indexed keywords

ESOPHAGEAL CANCER RELATED GENE 2; FORMYLPEPTIDE RECEPTOR LIKE 1; PLASMIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CELL DIVISION; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM;

CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 77249164152     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.001     Document Type: Article

References (21)

1. Su T., Liu H., and Lu S.H. Cloning and identification of cDNA fragments related to human esophageal cancer. Zhonghua Zhong Liu Za Zhi. 20 (1998) 254-257
2. Cui Y., Wang J., Zhang X., Lang R., Bi M., Guo L., and Lu S.H. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem. Biophys. Res. Co. 302 4 (2003) 904-915
3. Huang G., Hu Z., Li M., Cui Y., Li Y., Guo L., Jiang W., and Lu S.H. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 28 11 (2007) 2274-2281
4. Friedl P., and Wolf K. Timor-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3 (2003) 362-374
5. Czekay R.P., Aertgeerts K., Curriden S.A., and Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160 5 (2003) 781-791
6. Wei C.-H.Y. The urokinase receptor and integrins in cancer progression. Cell. Mol. Life Sci. 65 12 (2008) 1916-1932
7. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3 (2003) 489-501
8. Blasi F., and Carmeliet P. UPAR: a versatile signaling orchestrator. Nat. Rev. Mol. Cell Biol. 3 (2002) 932-943
9. Ahmed N., Oliva K., Wang Y., Quinn M., and Rice G. Downregulation of urokinase plasminogen activator receptor expression inhibits ERK signaling with concomitant suppression of invasiveness due to loss of uPAR-β1 integrin complex in colon cancer cells. Br. J. Cancer 89 (2003) 374-384
10. Chapman H.A., and Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb. Haemost. 86 (2001) 124-129
11. Ossowski L., and Aguirre-Ghiso J.A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12 (2000) 613-620
12. Resnati M., Pallavicini I., and Wang J.M. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl Acad. Sci. USA 99 3 (2002) 1359-1364
13. Mazzieri R., D'Alessio S., Kenmoe R.K., Ossowski L., and Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17 (2006) 367-378
14. Huang G., Wang D., Guo L., Zhao N., Li Y., and Lu S.H. Monoclonal antibodies to esophageal cancer-related gene2 protein. Hybridoma 24 (2005) 86-91
15. Cheng X., Shen Z., Yang J., Lu S.H., and Cui Y. ECRG2 disruption leads to centrosome amplification and spindle checkpoint defects contributing chromosome instability. J. Biol. Chem. 283 9 (2008) 5888-5898
16. Sidenius N., and Blasi F. The urokinase palsminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22 (2003) 205-222
17. Jezierska A., and Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med. Sci. Monit. 15 2 (2009) RA32-RA40
18. Bauer T.W., Liu W., and Fan F. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and Insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65 (2005) 7775-7781
19. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., and Chapman H.A. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol. Biol. Cell 12 10 (2001) 2975-2986
20. Wei Y., Czekay R.P., and Robillard L. Regulation of α5β1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168 3 (2005) 501-511
21. Wei Y., Yang X., Wilkins J., and Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144 (1999) 1285-1294